BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:elecoglipron readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of elecoglipron\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07534592-148@assetmemo.bio
DTSTAMP:20261121T005423Z
DTSTART;VALUE=DATE:20270125
DTEND;VALUE=DATE:20270126
SUMMARY:elecoglipron: Phase 1 readout est. (NCT07534592)
DESCRIPTION:elecoglipron\, phase 1.\nStudy: A Study to Investigate the Effe
 ct of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participant
 s\nEstimated primary completion: 25 January 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/elecoglipron#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07534592
URL:https://assetmemo.bio/drug/elecoglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07775404-148@assetmemo.bio
DTSTAMP:20261121T005423Z
DTSTART;VALUE=DATE:20280406
DTEND;VALUE=DATE:20280407
SUMMARY:elecoglipron: Phase 3 readout est. (NCT07775404)
DESCRIPTION:elecoglipron\, phase 3\, Obesity.\nStudy: A Study to Investigat
 e the Efficacy and Safety of Elecoglipron in Asian Participants With Obesi
 ty or Overweight With or Without Type 2 Diabetes Mellitus\nEstimated prima
 ry completion: 6 April 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/elecoglipron#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07775404
URL:https://assetmemo.bio/drug/elecoglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07664553-148@assetmemo.bio
DTSTAMP:20261121T005423Z
DTSTART;VALUE=DATE:20280523
DTEND;VALUE=DATE:20280524
SUMMARY:elecoglipron: Phase 3 readout est. (NCT07664553)
DESCRIPTION:elecoglipron\, phase 3\, Type 2 Diabetes.\nStudy: A Phase III S
 tudy to Investigate the Efficacy and Safety of Elecoglipron Compared With 
 Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin\nEst
 imated primary completion: 23 May 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/elecoglipron#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07664553
URL:https://assetmemo.bio/drug/elecoglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662213-148@assetmemo.bio
DTSTAMP:20261121T005423Z
DTSTART;VALUE=DATE:20280523
DTEND;VALUE=DATE:20280524
SUMMARY:elecoglipron: Phase 3 readout est. (NCT07662213)
DESCRIPTION:elecoglipron\, phase 3\, Type 2 Diabetes.\nStudy: A Study to Fi
 nd Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Me
 llitus by Comparing it With Semaglutide\, a Medicine Already Used to Treat
  Type 2 Diabetes Mellitus\nEstimated primary completion: 23 May 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/elecoglipron#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07662213
URL:https://assetmemo.bio/drug/elecoglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662109-148@assetmemo.bio
DTSTAMP:20261121T005423Z
DTSTART;VALUE=DATE:20280705
DTEND;VALUE=DATE:20280706
SUMMARY:elecoglipron: Phase 3 readout est. (NCT07662109)
DESCRIPTION:elecoglipron\, phase 3\, Type 2 Diabetes.\nStudy: A Phase III S
 tudy to Investigate the Efficacy and Safety of the Combination of Elecogli
 pron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus\nEstimated 
 primary completion: 5 July 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/elecoglipron#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07662109
URL:https://assetmemo.bio/drug/elecoglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662135-148@assetmemo.bio
DTSTAMP:20261121T005423Z
DTSTART;VALUE=DATE:20280713
DTEND;VALUE=DATE:20280714
SUMMARY:elecoglipron: Phase 3 readout est. (NCT07662135)
DESCRIPTION:elecoglipron\, phase 3\, Type 2 Diabetes.\nStudy: A Phase III S
 tudy to Investigate the Efficacy and Safety of Elecoglipron Compared With 
 Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Functio
 n on Background Dapagliflozin\nEstimated primary completion: 13 July 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/elecoglipron#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07662135
URL:https://assetmemo.bio/drug/elecoglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662044-148@assetmemo.bio
DTSTAMP:20261121T005423Z
DTSTART;VALUE=DATE:20280714
DTEND;VALUE=DATE:20280715
SUMMARY:elecoglipron: Phase 3 readout est. (NCT07662044)
DESCRIPTION:elecoglipron\, phase 3\, Type 2 Diabetes.\nStudy: A Phase III S
 tudy to Investigate the Efficacy and Safety of Elecoglipron Alone or in Co
 mbination With Dapagliflozin Compared With Placebo in Adults With Type 2 D
 iabetes Mellitus\nEstimated primary completion: 14 July 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/elecoglipron#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07662044
URL:https://assetmemo.bio/drug/elecoglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07667803-148@assetmemo.bio
DTSTAMP:20261121T005423Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:elecoglipron: Phase 3 readout est. (NCT07667803)
DESCRIPTION:elecoglipron\, phase 3\, Obesity.\nStudy: A Master Protocol to 
 Investigate Efficacy and Safety of Elecoglipron in Participants With Obesi
 ty or Overweight With or Without T2DM\nEstimated primary completion: 31 Ju
 ly 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/elecoglipron
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076
 67803
URL:https://assetmemo.bio/drug/elecoglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07761117-148@assetmemo.bio
DTSTAMP:20261121T005423Z
DTSTART;VALUE=DATE:20290903
DTEND;VALUE=DATE:20290904
SUMMARY:elecoglipron: Phase 3 readout est. (NCT07761117)
DESCRIPTION:elecoglipron\, phase 3\, Heart Failure.\nStudy: A Study to Inve
 stigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Parti
 cipants With HFpEF or HFmrEF\nEstimated primary completion: 3 September 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/elecoglipron#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07761117
URL:https://assetmemo.bio/drug/elecoglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07753993-148@assetmemo.bio
DTSTAMP:20261121T005423Z
DTSTART;VALUE=DATE:20301004
DTEND;VALUE=DATE:20301005
SUMMARY:elecoglipron: Phase 3 readout est. (NCT07753993)
DESCRIPTION:elecoglipron\, phase 3\, Chronic Kidney Disease.\nStudy: A Stud
 y to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult
  Participants With Chronic Kidney Disease.\nEstimated primary completion: 
 4 October 2030. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/eleco
 glipron#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07753993
URL:https://assetmemo.bio/drug/elecoglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
